This review discusses toripalimab and its role as an immunotherapeutic option for first-line and previously treated recurrent or metastatic nasopharyngeal carcinoma.
Guiding commentary has been provided by Professor Aaron Hansen, the Medical Director of Cancer Services at the Princess Alexandra Hospital, the Director of Clinical Trials at the Translational Research Institute, Professor at the Mayne School of Medicine, University of Queensland and Consultant Medical Oncologist at Greenslopes Private Hospital in Brisbane Australia.
Please login below to download this issue (PDF)